Following is information about some of the ongoing clinical trials that may be of interest to those treating individuals with pancreatic cancer.

Pancreatic Cancer

Losartan and Nivolumab in Combination with FOLFIRINOX and SBRT in Localized Pancreatic Cancer

Recruiting Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer.

This research study is studying a combination of interventions as a possible treatment for pancreatic tumor.

The interventions involved in this study are:

• Drug: FOLFIRINOX which is made up of four different drugs (5-Fluorouracil [5-FU], Oxaliplatin, Irinotecan and Leucovorin)
• Drug: Losartan
• Drug: Nivolumab
• Radiation Therapy​
• Surgery

Detailed Description:

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied.

The FDA (the U.S. Food and Drug Administration) has approved FOLFIRINOX as a treatment option for this disease.

The FDA has not approved Losartan or Nivolumab for this specific disease but they have been approved for other uses.

FOLFIRINOX is a combination of 4 chemotherapy agents that may help shrink the tumor before surgery. Losartan is a drug that is used to lower blood pressure. Nivolumab is an antibody (a cell that attaches to other cells to fight off infection) that may cause programmed cell death of cancer cells. Radiation therapy is believed to increase the likelihood of response of immunotherapy (the prevention/treatment of a disease through an immune response).

Study Design:

Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 160 participants
Allocation: Randomized
Primary Purpose: Treatment
Official TitleA Randomized Phase 2 Study of Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
Actual Study Start Date: August 10, 2018
Estimated Primary Completion Date: December 31, 2021
Estimated Study Completion Date: December 31, 2025

Massachusetts General Hospital
Boston, Massachusetts, United States

Brigham and Women's Hospital
Boston, Massachusetts, United States

Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer January 2018

Recruiting Phase II Anetumab Ravtansine in Pre-treated Mesothelin-Expressing Pancreatic Cancer.

• Drug: Anetumab Ravtansine

Yale Cancer Center​
New Haven, Connecticut, United States

Rutgers Cancer Institute of New Jersey​
New Brunswick, New Jersey, United States

Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States

The primary objective of this study is to:

  • Test the activity/response rate per RECIST 1.1 criteria of Anetumab Ravtansine in patients with advanced pancreatic cancer who stain for mesothelin expression

The secondary objectives of this study are to:

  • Time to Progression (TTP) defined as time from study treatment to RECIST 1.1 progression, or death (others going off study will be censored)
  • Toxicity in pancreatic cancer patients (at 6.5 mg/kg dose)

Creon® (Pancrelipase) Therapy for Subjects with Exocrine Pancreatic Insufficiency (EPI) due to Pancreatic Cancer

A double-blind, randomized, parallel design with 2 dose cohorts of pancrelipase in resected pancreatic cancer subjects and an open-label single dose cohort in non-resected pancreatic cancer subjects.

Principal Investigator: Dr. Lynt B Johnson, MD

Indication: Exocrine Pancreatic Insufficiency (EPI) in Pancreatic Cancer Subjects.

Number of sites: 35 (multi-center study) 

Learn more about the GW Liver and Pancreas Institute for Quality (LPIQ) >

Download our 2019 LPIQ Annual Report (PDF) >